3D011 08
Alternative Names: 3D011-08Latest Information Update: 15 Feb 2024
At a glance
- Originator 3D Medicines
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 11 Sep 2023 3D Medicines terminates a phase I trial in Solid tumours (Monotherapy, Second-line therapy or greater) in China (IV) due to the company's decision (NCT05099536)
- 24 Feb 2022 Phase-I clinical trials in Solid tumours (Monotherapy, Second-line therapy or greater) in China (IV) (NCT05099536)
- 03 Nov 2021 3D Medicines plans a phase I trial for Solid tumours (In adults, Late-stage disease) in China (IV, Injection) (NCT05099536)